RS55558B1 - Kristalni oblik pemirolasta - Google Patents

Kristalni oblik pemirolasta

Info

Publication number
RS55558B1
RS55558B1 RS20170003A RSP20170003A RS55558B1 RS 55558 B1 RS55558 B1 RS 55558B1 RS 20170003 A RS20170003 A RS 20170003A RS P20170003 A RSP20170003 A RS P20170003A RS 55558 B1 RS55558 B1 RS 55558B1
Authority
RS
Serbia
Prior art keywords
sodium
pemirolast
compound
salts
compounds
Prior art date
Application number
RS20170003A
Other languages
English (en)
Serbian (sr)
Inventor
Anett Perlberg
Martin Viertelhaus
Ulrika Rosenström
Karol Horvath
Original Assignee
Rspr Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rspr Pharma Ab filed Critical Rspr Pharma Ab
Publication of RS55558B1 publication Critical patent/RS55558B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)
RS20170003A 2009-06-16 2010-06-15 Kristalni oblik pemirolasta RS55558B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18735509P 2009-06-16 2009-06-16
US18734809P 2009-06-16 2009-06-16
PCT/GB2010/001168 WO2010146348A2 (en) 2009-06-16 2010-06-15 New crystalline form of pemirolast

Publications (1)

Publication Number Publication Date
RS55558B1 true RS55558B1 (sr) 2017-05-31

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170003A RS55558B1 (sr) 2009-06-16 2010-06-15 Kristalni oblik pemirolasta

Country Status (31)

Country Link
US (3) US20120157415A1 (enExample)
EP (2) EP3141549A1 (enExample)
JP (2) JP5722317B2 (enExample)
KR (2) KR20170049645A (enExample)
CN (1) CN102596202B (enExample)
AR (1) AR077915A1 (enExample)
AU (1) AU2010261540B2 (enExample)
BR (1) BRPI1015559A2 (enExample)
CA (1) CA2765408A1 (enExample)
CY (1) CY1118413T1 (enExample)
DK (1) DK2443120T3 (enExample)
EA (1) EA025865B1 (enExample)
ES (1) ES2613059T3 (enExample)
HR (1) HRP20170023T1 (enExample)
HU (1) HUE032978T2 (enExample)
IL (1) IL216670A (enExample)
LT (1) LT2443120T (enExample)
ME (1) ME02685B (enExample)
MX (1) MX2011013676A (enExample)
NZ (1) NZ596747A (enExample)
PL (1) PL2443120T3 (enExample)
PT (1) PT2443120T (enExample)
RS (1) RS55558B1 (enExample)
SA (1) SA114350792B1 (enExample)
SG (1) SG176295A1 (enExample)
SI (1) SI2443120T1 (enExample)
SM (2) SMT201700085T1 (enExample)
TW (1) TWI504599B (enExample)
UY (1) UY32711A (enExample)
WO (2) WO2010146341A2 (enExample)
ZA (1) ZA201109045B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005513A (es) * 2009-11-13 2012-06-19 Cardoz Ab Pemirolast para el tratamiento de inflamacion sistemica de bajo grado.
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
WO2016063085A1 (en) 2014-10-23 2016-04-28 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
CN110267661B (zh) * 2016-10-03 2021-08-03 布利本迅药业(上海)有限公司 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド［１，２―ａ］ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
HUE029336T2 (en) 2005-09-16 2017-02-28 Daiichi Sankyo Co Ltd For the preparation of an optically active diamine derivative and process
CN101610765A (zh) * 2006-12-18 2009-12-23 卡多兹公司 用于治疗炎症的新组合物
EP2107907B1 (en) * 2006-12-20 2012-02-01 Cardoz AB Combination of pemirolast and ramatroban for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
LT2443120T (lt) 2017-02-10
WO2010146348A3 (en) 2011-03-03
PT2443120T (pt) 2017-02-08
AU2010261540A1 (en) 2012-01-19
CA2765408A1 (en) 2010-12-23
CN102596202A (zh) 2012-07-18
US9006431B2 (en) 2015-04-14
EP2443120B1 (en) 2016-11-02
MX2011013676A (es) 2012-02-08
ZA201109045B (en) 2013-05-29
TWI504599B (zh) 2015-10-21
US20170202839A1 (en) 2017-07-20
SG176295A1 (en) 2012-01-30
KR20120032530A (ko) 2012-04-05
EP2443120A2 (en) 2012-04-25
EP3141549A1 (en) 2017-03-15
ES2613059T3 (es) 2017-05-22
UY32711A (es) 2011-01-31
WO2010146348A9 (en) 2012-05-03
PL2443120T3 (pl) 2017-04-28
WO2010146341A2 (en) 2010-12-23
SMT201700085T1 (it) 2017-03-08
IL216670A0 (en) 2012-02-29
AU2010261540B2 (en) 2016-04-14
AR077915A1 (es) 2011-10-05
WO2010146348A2 (en) 2010-12-23
DK2443120T3 (en) 2017-01-09
NZ596747A (en) 2014-01-31
US20120157415A1 (en) 2012-06-21
HRP20170023T1 (hr) 2017-03-10
JP2012530118A (ja) 2012-11-29
IL216670A (en) 2017-02-28
EA201200017A1 (ru) 2013-10-30
EA025865B1 (ru) 2017-02-28
HUE032978T2 (hu) 2017-11-28
SI2443120T1 (sl) 2017-04-26
TW201100422A (en) 2011-01-01
ME02685B (me) 2017-06-20
BRPI1015559A2 (pt) 2016-04-26
SA114350792B1 (ar) 2015-11-10
CN102596202B (zh) 2015-01-21
AU2010261540A2 (en) 2012-01-19
SMT201700085B (it) 2017-03-08
US20140329839A1 (en) 2014-11-06
CY1118413T1 (el) 2017-06-28
KR20170049645A (ko) 2017-05-10
JP5722317B2 (ja) 2015-05-20
WO2010146341A3 (en) 2011-03-03
JP2015120750A (ja) 2015-07-02

Similar Documents

Publication Publication Date Title
US20170202839A1 (en) Crystalline Form of Pemirolast
CN104703964B (zh) 取代氨基茚满‑和氨基萘满甲酸及其用途
EP1746099A1 (en) Mnk1 or Mnk2 inhibitors
JP2018515569A (ja) キナーゼを調節するための化合物の固体形態
TW200918525A (en) Compounds
Luo et al. Design, synthesis, biological evaluation, and docking study of new triazole-phenylacetamide derivatives as α-glucosidase inhibitors
CN101575333A (zh) 一种喹唑啉衍生物及其医药用途
US20160250217A1 (en) Crystalline form of pemirolast
HK1238628A1 (en) Crystalline form of pemirolast for use in the treatment of inflammations
HK1169385A (en) Crystalline form of pemirolast
HK1169385B (en) Crystalline form of pemirolast
CN116693521A (zh) 一种含色酮结构的噻唑烷二酮乙酯类化合物及其制备方法、药物组合物和应用
TW201028390A (en) Flavononol renin inhibitor compounds and methods of use thereof
CN107459491A (zh) 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途
WO2018066646A1 (ja) 尿素誘導体
TWI762581B (zh) 醯胺衍生物、及其用途
RU2459809C2 (ru) Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
JP4324687B2 (ja) ２−（３−ニトロベンゾイル）安息香酸誘導体を有効成分とする医薬
AU2010270596A1 (en) Stable crystalline polymorphs of the dipotassium salt of (S) -2- {4- [2- (2, 4-diamino-quinazolin-6-yl) -ethyl] -benzoylamino} -4-methylene-pentanedioic acid